



COPY OF PAPERS
ORIGINALLY FILED

1614 #6
ML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 15 2002

In re Application of: Manabu WADA et al.

Serial No.: 10/076,421

Group Art Unit: 1614 TECH CENTER 1600/291

Filed: February 19, 2002

Examiner: Unassigned

For: ANTI-HIV AGENTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class
Mail in an envelope addressed to:
Assistant Commissioner For Patents,
Washington, D.C. 20231 on: August 6, 2002
Name: James Rosier
Signature: James Rosier
Date: August 6, 2002

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. _____; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed _____.

ADDITIONAL INFORMATION

BEST AVAILABLE COPY

LANGUAGE

- ☒ All listed materials are in the English language; (except the Seki reference) see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
 - ☐ The reference(s): _____ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): _____, respectively.
 - ☐ (An) English-language translation(s) of the references: _____ is (are) provided.
 - ☐ A commercial English-language abstract of reference(s) _____ is (are) provided.
 - ☐ An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

FEES

- ☒ No fee is required for this Information Disclosure Statement because:
 - ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
 - ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
 - ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
 - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.

CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.



COPY OF PAPERS
ORIGINALLY FILED

DEPOSIT ACCOUNT


If a fee is due, attached is a check in the amount of \$ _____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

RECEIVED

AUG 15 2002

Respectfully submitted,

TECH CENTER 1600/2900



Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: HAYAK-9

Date: August 6, 2002
AJZ:jr

I hereby certify that this correspondence is being
deposited with the U.S. Postal Services as First Class
Mail in an envelope addressed to:
Assistant Commissioner For Patents
Washington, D.C. 20231 on August 6, 2002
Name: Janice S. Siler
Signature: Janice S. Siler
Date: August 6, 2002



RECEIVED

AUG 15 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1800/2900

PTO/SB/08A (08-00)

Type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/076,421
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 19, 2002
		First Named Inventor	Manabu WADA et al.
		Group Art Unit	1614
		Examiner Name	Unassigned
		Attorney Docket Number	HAYAK-9
Sheet	1	of	1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dzung H. NGUYEN et al., "Evidence for Budding of Human Immunodeficiency Virus Type 1 Selectively From Glycolipid-Enriched Membrane Lipid Rafts," JOURNAL OF VIROLOGY, Vol. 74, No. 7, pp. 3264-3272, April 2000.	
		Yuri KOSHELNICK et al., "Mechanisms of Signaling Through Urokinase Receptor and The Cellular Response," THROMBOSIS and HAEMOSTASIS, 82(2), pp. 305-311, 1999.	
		SEKI et al., Seikagaku, 71(5), pp.350-352, 1999.	
		C. AMIEL et al., "Interleukin-16 (IL-16) Inhibits Human Immunodeficiency Virus Replication in Cells From Infected Subjects, and Serum....," THE JOURNAL OF INFECTIOUS DISEASES, Vol. 179, pp. 83-91, 1999.	
		R. PAL et al., "Inhibition of HIV-1 Infection by the β -Chemokine MDC," SCIENCE, Vol. 278, October 24, 1997.	
		J.A. LEVY et al., "Controlling HIV Pathogenesis: The Role of The Noncytotoxic Anti-HIV Response of CD8 ⁺ T Cells," IMMUNOLOGY TODAY, Vol. 17, No. 5, pp. 217-224, May 1996.	
		F. COCCHI et al., "Identification of RANTES, MIP-1 α , and MIP-1 β as the Major HIV-Suppressive Factors....," SCIENCE, Vol. 270, pp. 1811-1815, December 15, 1995.	
		B. CHEN et al., "Distinct Modes of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed by Superinfection of Nonproductively....," JOURNAL OF VIROLOGY, Vol. 68, No. 2, pp. 654-660, February 1994.	
		A. FAUCI, "Host Factors and The Pathogenesis of HIV-Induced Disease," NATURE, Vol. 384, pp. 529-534, December 12, 1996.	
		Estelle OBERLIN et al., "The CXCR4 Chemokine SDF-1 is the Ligand for LESTR/fusin and Prevents Infection by T-cell-line-adapted HIV-1," NATURE, Vol. 382, pp. 833-835, August 29, 1996.	
		M. BAIER et al., "HIV Suppression by Interleukin-16," NATURE, Vol. 378, p. 563, December 7, 1995.	
		A. ADACHI et al., "Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Non-Human Cells Transfected with an Infectious Molecular Clone," JOURNAL OF VIROLOGY, Vol. 59, No. 2, pp. 284-291, August 1986.	
		M. Patrizia STOPPELLI et al., "Differentiation-Enhanced Binding of the Amino-Terminal Fragment of Human Urokinase Plasminogen Activator to a Specific Receptor on U937 Monocytes," PROC. NATL. ACAD. SCI. USA, Vol. 82, pp. 4939-4943, August 1985.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.